News

News


Ampio Pharmaceuticals Schedules 2012 Update Webcast
05/14/2012 | Press Release


Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion™ for the Treatment of Chronic Pain of Osteoarthritis of the Knee and Schedules May 16th Webcast to Update Shareholders
05/11/2012 | Press Release


Ampio Pharmaceuticals announces extended analysis of Ampion™ In the Knee (AIK) Study shows pain relief of osteoarthritis, 84 days after a single injection into the knee, is statistically significant
04/30/2012 | Press Release


Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
04/27/2012 | Press Release


Ampio Pharmaceuticals Announces Presentation at Imperial Capital 2012 Healthcare Investor Forum
04/16/2012 | Press Release


Ampio Completes Patient Enrollment for Its Oxidation Reduction Potential (ORP) Clinical Trials
04/12/2012 | Press Release


Ampio Submits Type B Pre IND Meeting Request to the FDA for Zertane™
04/09/2012 | Press Release


Ampio Reaches Agreement with the TGA for the Submission Plan for Zertane in Australia
04/02/2012 | Press Release


Ampio Pharmaceuticals Announces the Licensing of Zertane™ to FBM Industria Farmaceutica Ltda to Commercialize in Brazil
03/22/2012 | Press Release


Ampio Strengthens Patent Protection for Lead Drug Ampion™
03/20/2012 | Press Release


Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
03/19/2012 | Press Release


Ampio Pharmaceuticals Announces Presentation at Cowen & Company 32nd Annual Health Care Conference
03/05/2012 | Press Release


Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
02/09/2012 | Press Release


Ampio Pharmaceuticals, Inc. Announces Statistically Significant Improvement in Pain Relief for its Lead Product, Ampion™ in the Osteoarthritis of the Knee Trial
01/31/2012 | Press Release


Register Now For AMPIO’s January 26, 2012 Outlook Call
01/26/2012 | News


Ampio Pharmaceuticals' Zertane™ Patent Estate Bolstered by Two New European Patents
01/17/2012 | Press Release


Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
01/17/2012 | Press Release


Executive Changes at Ampio
01/09/2012 | Press Release


Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
01/05/2012 | Press Release


Ampio Pharmaceuticals Completes Expanded Patient Enrollment for Ampion™ In Osteoarthritis of the Knee Clinical Trial in Australia
01/03/2012 | Press Release


Years: 2012 | 2011 | 2010

Learn More About:

Premature Ejaculation (PE)

Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.

Diabetic Retinopathy

A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness

Diabetic Nephropathy

A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis

AMPE Stock Quote - delayed
Last Change
AMPE 2.67 Down 0.14 (4.98%)

Ampio News

05/14/2012 | Press Release

Ampio Pharmaceuticals Schedules 2012 Update Webcast

05/11/2012 | Press Release

Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion™ for the Treatment of Chronic Pain of Osteoarthritis of the Knee and Schedules May 16th Webcast to Update Shareholders

04/30/2012 | Press Release

Ampio Pharmaceuticals announces extended analysis of Ampion™ In the Knee (AIK) Study shows pain relief of osteoarthritis, 84 days after a single injection into the knee, is statistically significant

» See all Ampio news